Cryotherapy is associated with improved clinical outcomes of sorafenib for the treatment of advanced hepatocellular carcinoma

Experimental and Therapeutic Medicine

Volumn 3, Issue 2, 2012, Pages 171-180

  Yang, Yongping ^a,b   Lu, Yinying ^a   Wang, Chunping ^a   Bai, Wenlin ^a   Qu, Jianhui ^a,b   Chen, Yan ^a   Chang, Xiujuan ^a   An, Linjing ^a   Zhou, Lin ^a   Zeng, Zhen ^a   Lou, Min ^a   Lv, Jiyun ^a  

^a BEIJING 302 HOSPITAL   (China)

^b Beijing Institute of Infectious Diseases   (China)

Author keywords

Cryotherapy; Efficacy; Hepatocellular carcinoma; Microvessel density; Safety; Sorafenib

Indexed keywords

CD34 ANTIGEN; LAMIVUDINE; SORAFENIB;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; ALOPECIA; ANEMIA; ARTICLE; CANCER GROWTH; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYOTHERAPY; DIARRHEA; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FOLLOW UP; HAND FOOT SKIN REACTION; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; IMMUNOHISTOCHEMISTRY; LIFE EXPECTANCY; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MICROVESSEL DENSITY; OVERALL SURVIVAL; PORTAL VEIN THROMBOSIS; RASH; SIDE EFFECT; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER GASTROINTESTINAL BLEEDING; VOICE CHANGE; WEIGHT REDUCTION;

EID: 84855405210     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2011.398     Document Type: Article

References (41)

1. Parkin DM: Global cancer statistics in the year 2000. Lancet Oncol 2: 533-43, 2001.
2. Tang ZY: Perspective of clinical onology from the viewpoint of liver cancer studies. Tumor (China) 29: 1-4, 2009.
3. Yoo HY, Patt CH, Geschwind JF, et al: The outcome of liver transplantation in patients with hepatocellular carcinoma in the United States between 1988 and 2001: 5-year survival has improved significantly with time. J Clin Oncol 21: 4329-4335, 2003.
4. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, Hsiao CK, Chen PJ, Chen DS and Chen CJ: Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 347: 168-174, 2002.
5. Sherman M: Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis 25: 143-154, 2005.
6. Llovet JM, Burroughs A and Bruix J: Hepatocellular carcinoma. Lancet 362: 1907-1917, 2003.
7. Llovet JM, Burroughs A and Bruix J: Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19: 329-338, 1999.
8. Bruix J and Llovet JM: Prognosis prediction and treatment strategy in hepatocellular carcinoma. Hepatology 35: 519-524, 2002.
9. Bruix J and Sherman M: Management of hepatocellular carcinoma. Hepatology 42: 1208-1236, 2005.
10. Park KW, Park JW, Choi JI, et al: Survival analysis of 904 patients with hepatocellular carcinoma in a hepatitis B virus-endemic area. J Gastroenterol Hepatol 23: 467-473, 2008.
11. Llovet JM, Fuster J, Bruix J and The Barcelona-Clinic Liver Cancer Group: The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl 10 (Suppl 1): 115-120, 2004.
12. Cheng AL, Kang YK, Chen Z, et al: Randomized phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma. Lancet Oncol 10: 25-34, 2009.
13. Llovet JM, Ricci S, Mazzaferro V, et al; SHARP Investigators Study Group: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 359: 378-390, 2008.
14. Furuse J: Sorafenib for the treatment of unresectable hepatocellular carcinoma. Biologics 2: 779-788, 2008.
15. Hakimé A, Hines-Peralta A, Peddi H, et al: Combination of radiofrequency ablation with antiangiogenic therapy for tumor ablation efficacy: study in mice. Radiology 244: 464-470, 2007.
16. Osada S, Imai H, Tomita H, et al: Serum cytokine levels in response to hepatic cryoablation. J Surg Oncol 95: 491-498, 2007.
17. Poston G: Cryosurgery for colorectal liver metastases. Hepatogastroenterol 48: 323-324, 2001.
18. Lee FT Jr, Mahvi DM, Chosy SG, Onik GM, Wong WS, Littrup PJ and Scanlan KA: Hepatic cryosurgery with intraoperative US guidance. Radiology 202: 624-632, 1997.
19. Shock SA, Laeseke PF, Sampson LA, Lewis WD, Winter TC III, Fine JP and LEE FT Jr: Hepatic hemorrhage caused by percutaneous tumor ablation: radiofrequency ablation versus cryoablation in a porcine model. Radiology 236: 125-131, 2005.
20. Atwell TD, Farrell MA, Callstrom MR, Charboneau JW, Leibovich BC, Patterson DE, Chow GK and Blute ML: Percutaneous cryoablation of 40 solid renal tumors with US guidance and CT monitoring: initial experience. Radiology 243: 276-83, 2007.
21. Jungraithmayr W, Burger D, Olschewski M and Eggstein S: Cryoablation of malignant liver tumor: results of a single center study. Hepatobiliary Pancreat Dis Int 4: 554-560, 2005.
22. Yamamoto J, Kosuge T, Saiura A, et al: Effectiveness of hepatic resection for early-stage hepatocellular carcinoma in cirrhotic patients: subgroup analysis according to Milan Criteria. Jpn J Clin Ocncol 34: 287-295, 2007.
23. Lencioni R and Llovet JM: Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30: 52-60, 2010.
24. Trotti A, Colevas AD, Setser A, et al: CTCAE v 3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13: 176-181, 2003.
25. Wang C, Lu Y, Chen Y, Feng Y, An L, Wang X, Su S, Bai W, Zhou L, Yang Y and Xu D: Prognostic factors and recurrence of hepatitis B-related hepatocellular carcinoma after argon-helium cryoablation: a prospective study. Clin Exp Metastasis 26: 839-848, 2009.
26. Poon RT, Ng IO, Lau C, Yu WC, Yang ZF, Fan ST and Wong J: Tumor microvessel density as a predictor recurrence after resection of hepatocellular carcinoma: a prospective study. J Clin Oncol 20: 1775-1785, 2002.
27. Yau T, Chan P, Ng KK, et al: Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. Cancer 115: 428-436, 2009.
28. Greten TF, Korangy F, Manns MP and Malek NP: Molecular therapy for the treatment of hepatocellular carcinoma. Br J Cancer 100: 19-23, 2009.
29. Zuro LM and Staren ED: Cryosurgical ablation of unresectable hepatic tumors. AORN J 64: 231-6, 239-44, 1996.
30. Shimizu T, Sakuhara Y, Abo D, Hasegawa Y, Kodama Y, Endo H, Shirato H and Miyasaka K: Outcome of MR-guided percutaneous cryoablation for hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 16: 816-823, 2009.
31. Shim JH, Park JW, Choi JI, Park BJ and Kim CM: Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcnoma patients in a Hepatitis B virus-endemic area. J Cancer Res Clin Oncol 135: 617-625, 2009.
32. Pinter M, Sieghart W, Graziadei I, Vogel W, Maieron A, Königsberg R, Weissmann A, Kornek G, Plank C and Peck-Radosavljevic M: Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. Oncologist 14: 70-76, 2009.
33. Kane RC, Farrell AT, Madabushi R, et al: Sorafenib for the treatment of unresectable hepatocellular carcinoma. Oncologist 14: 95-100, 2009.
34. Furuse J, Ishii H, Nakachi K, et al: Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci 99: 159-165, 2008.
35. Wörns MA, Weinmann A, Pfingst K, et al: Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J Clin Gastroenterol 43: 489-495, 2009.
36. Vincenzi B, Santini D, Russo A, et al: Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologist 15: 85-92, 2010.
37. Schramm C, Schuch G and Lohse AW: Sorafenib-induced liver failure. Am J Gastroenterol 103: 2162-2163, 2008.
38. Semela D and Dufour JF: Angiogenesis and hepatocellular carcinoma. J Hepatol 41: 864-880, 2004.
39. Liu L, Cao Y, Chen C, et al: Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66: 11851-11858, 2006.
40. Li M, Li H, Li C, Guo L, Liu H, Zhou S, Liu X, Chen Z, Shi S, Wei J, McNutt MA and Li G: Cytoplasmic alpha-fetoprotein functions as a co-repressor in RA-RAR signaling to promote the growth of human hepatoma Bel 7402 cells. Cancer Lett 285: 190-199, 2009.
41. Li M, Li H, Li C, Zhou S, Guo L, Liu H, Jiang W, Liu X, Li P, McNutt MA and Li G: Alpha fetoprotein is a novel protein-binding partner for caspase-3 and blocks the apoptotic signaling pathway in human hepatoma cells. Int J Cancer 124: 2845-2854, 2009.